Neural Regeneration Research ›› 2024, Vol. 19 ›› Issue (8): 1647-1648.doi: 10.4103/1673-5374.387984

Previous Articles     Next Articles

The big data challenge – and how polypharmacology supports the translation from pre-clinical research into clinical use against neurodegenerative diseases and beyond

Sven Marcel Stefan*, #, Muhammad Rafehi*, ##br#   

  1. Drug Development and Chemical Biology, Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck and University Medical Center Schleswig-Holstein, Lübeck, Germany; Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Oslo, Norway; School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia (Stefan SM)
    Institute of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany; Department of Medical Education, Augsburg University Medicine, Augsburg, Germany (Rafehi M)
  • Online:2024-08-15 Published:2024-01-03
  • Contact: Sven Marcel Stefan, PhD, svenmarcel.stefan@uksh.de; Muhammad Rafehi, PhD, muhammad.rafehi@med.uni-goettingen.de.
  • Supported by:
    This work was supported by the Walter Benjamin and Research Grant Programs of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, Germany; #446812474, #504079349 [PANABC]) (to SMS); the DFG (#437446827) and the Research Program of the University Medical Center Göttingen (to MR).

PDF

34

Abstract: Introductory comments: The identification and validation of disease-modifying proteins are fundamental aspects in drug development. However, the multifactority of neurodegenerative diseases poses a real challenge for targeted therapies. Furthermore, the behavior of individually (over-)expressed target proteins in vitro is likely to differ from their actual functional behavior when embedded in cascades and pathways in vivo. Increased compartmentalization, e.g., in the brain, adds to the complexity.